Moderna Seeks FDA Approval For COVID-19 Booster Shot_老虎社区_美港股上老虎

Moderna Seeks FDA Approval For COVID-19 Booster Shot

Benzinga2021-09-02

Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster. What Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

KS_Lee
·2021-09-02
Probably will break 400 today and if approved the booster likely to retest recent all time high.
回复
1
举报
收起
- Littlenoobie:
  Ok
  2021-09-02
  回复
  举报
ElginLow
·2021-09-02
Nice
回复
3
举报
YauDK
·2021-09-02
Oh ye ye pls like and comment
回复
2
举报
TeikLeong
·2021-09-02
Like
回复
3
举报
收起
- ChowCCJ:
  Done
  2021-09-02
  回复
  举报
Wee93
·2021-09-02
Good
回复
1
举报
CSL1m
·2021-09-02
Like
回复
4
举报
收起
- Footixx:
  👍
  2021-09-02
  回复
  举报
lyokel
·2021-09-02
Ok
回复
3
举报
DesmondChin
·2021-09-02
Have you settled the containment issues at Japan?
回复
3
举报
收起
- lyokel:
  haha
  2021-09-02
  回复
  举报
leekanghao
·2021-09-02
Here we go again
回复
4
举报
ronaldng
·2021-09-02
Lik
回复
4
举报
收起
- Wee93:
  done
  2021-09-02
  回复
  举报
JKJKJK
·2021-09-02
Pls help to like
回复
6
举报
收起
- RonnieO:
  Ok
  2021-09-02
  回复
  举报
- ronaldng:
  o
  2021-09-02
  回复
  举报
- AtwoZ:
  Done
  2021-09-02
  回复
  举报
assassinyj
·2021-09-02
😂
回复
7
举报
收起
- assassinyj:
  Haha
  2021-09-02
  回复
  举报
Jjjjia
·2021-09-02
Like pls
回复
7
举报
aliciatng
·2021-09-02
Like tq
回复
6
举报
收起
- Jjjjia:
  Done
  2021-09-02
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1188874540?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-09-02 16:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188874540","market":"us","top_or_hot":-1,"title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","media":"Benzinga","content":"<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">网页链接</a>\n\n</div>\n","source":"lsy1606299360108","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","article_id":"1188874540","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","pubTimestamp":1630571264,"sourceInfo":{"source_id":"lsy1606299360108","name":"Benzinga"},"weMediaInfo":null,"summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"莫德纳寻求美国食品和药物管理局批准新冠肺炎强化注射","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":812850468,"gmtCreate":1630575715854,"gmtModify":1631892765408,"author":{"id":"3579578865458065","authorId":"3579578865458065","authorIdStr":"3579578865458065","name":"KS_Lee","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579578865458065"},"htmlText":"Probably will break 400 today and if approved the booster likely to retest recent&nbsp;all time high.&nbsp;","listText":"Probably will break 400 today and if approved the booster likely to retest recent&nbsp;all time high.&nbsp;","text":"Probably will break 400 today and if approved the booster likely to retest recent all time high.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/812850468","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5729236,"gmtCreate":1630575924234,"gmtModify":1631892765407,"authorId":4087110853440910,"author":{"id":4087110853440910,"authorId":4087110853440910,"name":"Littlenoobie","avatar":"https://static.tigerbbs.com/02d08b3ef6fcfd7e08dcc2b8ebf67301","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812850468,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":812850874,"gmtCreate":1630575675198,"gmtModify":1631890511573,"author":{"id":"3578313543552744","authorId":"3578313543552744","authorIdStr":"3578313543552744","name":"ElginLow","avatar":"https://static.tigerbbs.com/44d66a2d7ac712e903ddee8420e88c27","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3578313543552744"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812850874","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":812829347,"gmtCreate":1630574897789,"gmtModify":1631893611505,"author":{"id":"3580072870029753","authorId":"3580072870029753","authorIdStr":"3580072870029753","name":"YauDK","avatar":"https://static.tigerbbs.com/4e00c10df4000c04392220903422d15f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3580072870029753"},"htmlText":"Oh ye ye pls like and comment&nbsp;","listText":"Oh ye ye pls like and comment&nbsp;","text":"Oh ye ye pls like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812829347","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":812882706,"gmtCreate":1630573556005,"gmtModify":1631890918494,"author":{"id":"3581504913688063","authorId":"3581504913688063","authorIdStr":"3581504913688063","name":"TeikLeong","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3581504913688063"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/812882706","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5729030,"gmtCreate":1630574088814,"gmtModify":1635132905352,"authorId":3575375342391732,"author":{"id":3575375342391732,"authorId":3575375342391732,"name":"ChowCCJ","avatar":"https://static.tigerbbs.com/bc5fafdf3c6b7c87a4217f2f73a89adb","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812882706,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"EN"},{"id":812888523,"gmtCreate":1630573281262,"gmtModify":1631892754222,"author":{"id":"3559122008797693","authorId":"3559122008797693","authorIdStr":"3559122008797693","name":"Wee93","avatar":"https://static.tigerbbs.com/68f347275fc58792610a1f69df23fb2f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3559122008797693"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812888523","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":812889502,"gmtCreate":1630573104506,"gmtModify":1631886879772,"author":{"id":"3568421726936497","authorId":"3568421726936497","authorIdStr":"3568421726936497","name":"CSL1m","avatar":"https://static.tigerbbs.com/49565bb8d6cdc108dcbc0e1cb24f57f7","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3568421726936497"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/812889502","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5728917,"gmtCreate":1630573242398,"gmtModify":1631886879774,"authorId":3572228950547010,"author":{"id":3572228950547010,"authorId":3572228950547010,"name":"Footixx","avatar":"https://static.tigerbbs.com/286a694c51da40f13325f2f7cd6b8851","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812889502,"type":1,"supId":0,"prevId":0,"content":"👍","text":"👍","html":"👍"}],"langContent":"EN"},{"id":812812911,"gmtCreate":1630572634533,"gmtModify":1631892203457,"author":{"id":"3563941452424650","authorId":"3563941452424650","authorIdStr":"3563941452424650","name":"lyokel","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3563941452424650"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812812911","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":812816535,"gmtCreate":1630572603327,"gmtModify":1631885820476,"author":{"id":"3578983795474363","authorId":"3578983795474363","authorIdStr":"3578983795474363","name":"DesmondChin","avatar":"https://static.tigerbbs.com/b90cb6b6a6c328ac8d02a829e5e7c835","vip":1,"hat":"https://static.tigerbbs.com/46b6808e1ba3716fb9c53339adffa3c5","crmLevel":3,"crmLevelSwitch":0,"idStr":"3578983795474363"},"htmlText":"Have you settled the containment issues at Japan?&nbsp;","listText":"Have you settled the containment issues at Japan?&nbsp;","text":"Have you settled the containment issues at Japan?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/812816535","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5728821,"gmtCreate":1630572629190,"gmtModify":1631885820478,"authorId":3563941452424650,"author":{"id":3563941452424650,"authorId":3563941452424650,"name":"lyokel","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812816535,"type":1,"supId":0,"prevId":0,"content":"haha","text":"haha","html":"haha"}],"langContent":"EN"},{"id":812810685,"gmtCreate":1630572154847,"gmtModify":1632472307558,"author":{"id":"3583978426873835","authorId":"3583978426873835","authorIdStr":"3583978426873835","name":"leekanghao","avatar":"https://static.tigerbbs.com/3c1122e49e06c919b85c00976e928d03","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583978426873835"},"htmlText":"Here we go again","listText":"Here we go again","text":"Here we go again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812810685","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":812832144,"gmtCreate":1630571758488,"gmtModify":1631892323829,"author":{"id":"3573522326711377","authorId":"3573522326711377","authorIdStr":"3573522326711377","name":"ronaldng","avatar":"https://static.tigerbbs.com/1f871cfd738787c8daf99ae3c46baf0f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573522326711377"},"htmlText":"Lik","listText":"Lik","text":"Lik","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/812832144","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5728925,"gmtCreate":1630573273250,"gmtModify":1631892324531,"authorId":3559122008797693,"author":{"id":3559122008797693,"authorId":3559122008797693,"name":"Wee93","avatar":"https://static.tigerbbs.com/68f347275fc58792610a1f69df23fb2f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812832144,"type":1,"supId":0,"prevId":0,"content":"<u>done</u>","text":"<u>done</u>","html":"<u>done</u>"}],"langContent":"EN"},{"id":812836083,"gmtCreate":1630571653042,"gmtModify":1631890338608,"author":{"id":"3581988841626176","authorId":"3581988841626176","authorIdStr":"3581988841626176","name":"JKJKJK","avatar":"https://static.tigerbbs.com/882030abc3e0ffb1122b6a566ab01832","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581988841626176"},"htmlText":"Pls help to like","listText":"Pls help to like","text":"Pls help to like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/812836083","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5728990,"gmtCreate":1630573706437,"gmtModify":1631890338634,"authorId":4088850777374920,"author":{"id":4088850777374920,"authorId":4088850777374920,"name":"RonnieO","avatar":"https://static.tigerbbs.com/1292a5981b699a40c70f37718afa2985","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812836083,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":5728723,"gmtCreate":1630571762821,"gmtModify":1631890338622,"authorId":3573522326711377,"author":{"id":3573522326711377,"authorId":3573522326711377,"name":"ronaldng","avatar":"https://static.tigerbbs.com/1f871cfd738787c8daf99ae3c46baf0f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812836083,"type":1,"supId":0,"prevId":0,"content":"o","text":"o","html":"o"},{"id":5728722,"gmtCreate":1630571757799,"gmtModify":1631890338611,"authorId":3586254379286032,"author":{"id":3586254379286032,"authorId":3586254379286032,"name":"AtwoZ","avatar":"https://static.tigerbbs.com/7347da48f4f74369b5ff3a53a2e36a45","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812836083,"type":1,"supId":0,"prevId":0,"content":"<u>Done</u>","text":"<u>Done</u>","html":"<u>Done</u>"}],"langContent":"EN"},{"id":812838948,"gmtCreate":1630571602984,"gmtModify":1631888903282,"author":{"id":"3570795138700824","authorId":"3570795138700824","authorIdStr":"3570795138700824","name":"assassinyj","avatar":"https://static.tigerbbs.com/c5c10786bc09238ddcb1c4b89e9cfa6e","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3570795138700824"},"htmlText":"😂&nbsp;","listText":"😂&nbsp;","text":"😂","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/812838948","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5728706,"gmtCreate":1630571607969,"gmtModify":1631888903413,"authorId":3570795138700824,"author":{"id":3570795138700824,"authorId":3570795138700824,"name":"assassinyj","avatar":"https://static.tigerbbs.com/c5c10786bc09238ddcb1c4b89e9cfa6e","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812838948,"type":1,"supId":0,"prevId":0,"content":"Haha","text":"Haha","html":"Haha"}],"langContent":"EN"},{"id":812839264,"gmtCreate":1630571441658,"gmtModify":1632472331568,"author":{"id":"4087709618925430","authorId":"4087709618925430","authorIdStr":"4087709618925430","name":"Jjjjia","avatar":"https://static.tigerbbs.com/25215d9b4b22838734cba07948cafe46","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087709618925430"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812839264","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":812830745,"gmtCreate":1630571402687,"gmtModify":1632472334592,"author":{"id":"3572214398550610","authorId":"3572214398550610","authorIdStr":"3572214398550610","name":"aliciatng","avatar":"https://static.tigerbbs.com/c4b23ee891a1061c7907495a9c7da890","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3572214398550610"},"htmlText":"Like tq","listText":"Like tq","text":"Like tq","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/812830745","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5728679,"gmtCreate":1630571454383,"gmtModify":1631895283676,"authorId":4087709618925430,"author":{"id":4087709618925430,"authorId":4087709618925430,"name":"Jjjjia","avatar":"https://static.tigerbbs.com/25215d9b4b22838734cba07948cafe46","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812830745,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":74,"commentSize":14,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}